Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00272
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
PDC-CPT2
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Tumor
|
|||||
| Structure |
|
|||||
| Peptide Name |
Cyclic peptide [W(WR)4K(βAla)]
|
Peptide Info | ||||
| Drug Name |
Camptothecin
|
Drug Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
3-(3-((2-(carboxyamino)ethyl)disulfaneyl)propanamido)propanoic acid
|
Linker Info | ||||
| Peptide Modified Type |
Amino acid modifications; Cyclization modification
|
|||||
| Modified Segment |
One arginine was replaced with one lysine
|
|||||
| Formula |
C114H138N32O17S2
|
|||||
| #Ro5 Violations (Lipinski): 4 | Molecular Weight | 2292.699 | ||||
| Lipid-water partition coefficient (xlogp) | 3.91248 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 30 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 25 | |||||
| Rotatable Bond Count (rotbonds) | 43 | |||||
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Tumor | ||||
| Efficacy Data | Cell viability |
80%
|
|||
| Administration Time | 72 h | ||||
| Administration Dosage | 5 µM | ||||
| Evaluation Method | MTT assay | ||||
| Description |
Antiproliferative results showed that PTX1 inhibited cell proliferation by 18.7%. The anti-proliferative activity of CPT1 was diminished by 1.9-fold as compared to CPT whereas the activity of CPT2 was comparable to CPT, since CPT2 reduced the cell viability to 61%.
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cell | CVCL_0031 | ||
References